Cardiovascular risks are common within diabetic patients with CKD, when such risk jeopardize the wellbeing of the patient, SGLT2i, finerenone and GLP-1 analogues are all apposite recommendations, but when the risk of renal events heightens, then SGLT2i will be the sole recommendation available. This evidence concerns the gene GLP1R and chronic kidney disease.